ALBLU.PA down 51% YTD on EURONEXT pre-market: assess near-term risks
ALBLU.PA stock opens pre-market on EURONEXT at €0.48, down 51.00% YTD and ranking among the session’s top losers. Trading volume is light at 2,344 shares versus a 50-day average of 3,965. Investors face weak profitability with EPS -0.06 and PE -8.58, and a small market cap of €9,438,476.00. This note explains drivers behind the drop, highlights key ratios, and flags near-term price targets for Europe-listed Bluelinea SA (ALBLU.PA)
ALBLU.PA stock pre-market movers and price action
ALBLU.PA stock trades at €0.48 pre-market on EURONEXT after opening at €0.51 and hitting a day high of €0.51. Volume of 2,344 is slightly below average, at a relative volume of 1.05. The share remains close to its 50-day average (€0.48) and below the 200-day average (€0.55).
Why the share price is falling: earnings and fundamentals
Bluelinea SA reports negative earnings with EPS -0.06 and a trailing PE of -8.58, reflecting losses. The company shows weak liquidity with a current ratio of 0.46 and high debt metrics: debt to equity of 7.48 and debt ratio 0.56. These fundamentals explain investor caution and the stock’s long-term decline of -47.31% over 1 year.
Valuation and cash flow metrics for ALBLU.PA stock
Valuation is mixed: price-to-sales is 0.92, but price-to-book is elevated at 9.18, signaling limited equity cushion. Free cash flow per share is -0.05 and operating cash flow per share is 0.03, showing weak cash generation. Enterprise value to sales stands at 1.38, while EV/EBITDA is negative, reflecting losses.
Technical setup on EURONEXT and short-term signals
Technicals show momentum but limited conviction: RSI is 62.29, CCI reads 145.85 and ADX is 29.13, indicating a strong trend but overbought oscillators. Bollinger Bands sit €0.44–€0.50, and MACD is near neutral. These signals can produce volatile swings around the current €0.48 price.
Meyka AI grade, forecast and analyst consensus
Meyka AI rates ALBLU.PA with a score out of 100: 64.93 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Company-level ratings differ: a third-party company rating shows D+ / Strong Sell on 2025-02-28, reflecting poor profitability and balance-sheet strain.
Meyka AI’s forecast model projects a quarterly price of €0.40 and a monthly price of €0.35. Compared with the current €0.48, the quarterly projection implies an implied downside of -17.01% and the monthly projection implies -27.38%. Forecasts are model-based projections and not guarantees.
Price targets, scenarios and sector context for ALBLU.PA
We present three realistic scenarios for ALBLU.PA stock on EURONEXT in EUR: Bear target €0.25, Base target €0.40, Bull target €0.75. The base target aligns with Meyka AI’s quarterly forecast of €0.40. Bluelinea sits in the Healthcare / Medical – Devices sector where average PE and PB are materially higher, so ALBLU.PA’s weak margins and elevated leverage increase downside risk relative to peers.
Final Thoughts
ALBLU.PA stock is a top pre-market loser on EURONEXT, trading at €0.48 with low liquidity and stretched balance-sheet metrics. Key negatives include EPS -0.06, debt to equity 7.48, and a current ratio of 0.46, which explain the stock’s poor performance YTD. Meyka AI’s model projects €0.40 quarterly and €0.35 monthly prices, implying potential near-term downside of -17.01% to -27.38% versus the current price. Our scenario targets range from €0.25 (bear) to €0.75 (bull), with a base case at €0.40 reflecting ongoing margin pressure and small market cap of €9,438,476.00. Investors should weigh sector comparables and the company’s weak cash flow before adding exposure. Meyka AI, an AI-powered market analysis platform, provides these model-based projections. Forecasts and the Meyka grade are informational only and not guarantees; we are not financial advisors.
FAQs
ALBLU.PA stock is pressured by weak earnings (EPS **-0.06**), a low current ratio (**0.46**), and high debt-to-equity (**7.48**). These fundamentals, plus low liquidity and underperformance versus sector peers, drive selling ahead of the open.
Meyka AI’s forecast model projects a quarterly price of **€0.40** and a monthly price of **€0.35**. Compared with the current **€0.48**, the model implies near-term downside of **-17.01%** to **-27.38%**. Forecasts are model-based projections and not guarantees.
We give a bear target **€0.25**, base **€0.40**, and bull **€0.75** on EURONEXT. The base aligns with Meyka AI’s quarterly forecast and reflects weak margins and leverage versus Healthcare peers.
ALBLU.PA shows weaker liquidity and profitability than the Healthcare sector, which typically posts higher PE and PB ratios. Bluelinea’s margin and leverage metrics place it below sector averages and increase relative risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
